Trump’s Marijuana Move DIVIDES GOP – Chaos Looms

(LibertySociety.com) – President Trump’s Justice Department stands ready to reclassify marijuana from Schedule I to III, delivering tax relief to businesses while igniting fierce backlash from conservative Republicans who warn it empowers cartels and endangers public safety.

Story Snapshot

DOJ expected to finalize marijuana rescheduling as soon as Wednesday, moving it from Schedule I (no medical use) to Schedule III (accepted medical uses, lower abuse potential).
Eliminates Section 280E taxes, slashing effective rates from 40% to 8-10% for state-legal cannabis firms, boosting profitability without federal legalization.
Trump’s December 2025 executive order expedited the process started under Biden, emphasizing medical research and CBD access amid GOP congressional fury.
Conservative lawmakers, led by Reps. Sessions and Harris, decry the move as a threat to children, roads, and anti-drug efforts, exposing party rifts.
Advances research on pain, nausea, and anorexia treatments, but maintains federal illegality and tightens hemp THC limits.

DOJ Poised for Imminent Rescheduling

The U.S. Justice Department anticipates finalizing marijuana’s reclassification from Schedule I to Schedule III as early as Wednesday, according to an insider familiar with the matter. This shift recognizes accepted medical uses like treating chemotherapy-induced nausea, pain, and anorexia, while acknowledging lower abuse potential compared to heroin or LSD. President Trump’s December 18, 2025, executive order accelerated the process originally initiated by Biden in 2022. HHS recommended the change in 2023 based on scientific evaluations, followed by DEA’s proposed rule in May 2024 that drew 43,000 public comments. The move eases federal barriers without nationwide legalization, preserving state primacy in medical programs across 40 states plus DC.

Tax Relief Transforms Cannabis Industry

Reclassification eliminates Section 280E taxes, which currently impose a roughly 40% effective rate on state-legal cannabis businesses by disallowing standard deductions. Bloomberg Intelligence projects rates dropping to 8-10%, providing immediate profitability boosts and enabling reinvestment in operations. This relief addresses long-standing federal-state conflicts, where Congress via the Rohrabacher-Farr amendment already shields state medical programs from prosecution. Trump’s order also directs access to full-spectrum CBD products, countering November 2025 hemp restrictions limiting THC to 0.4mg per container. Cannabis firms, major stakeholders, stand to gain most from reduced financial burdens and expanded research opportunities.

Trump’s Executive Push Meets Conservative Resistance

President Trump signed the executive order to expedite rescheduling and promote CBD research, including a Medicare pilot for certain products. This bipartisan thread—Biden’s review to Trump’s finish—highlights executive action amid congressional gridlock. However, 26 House Republicans, led by Rep. Pete Sessions (R-TX) and Freedom Caucus Chair Andy Harris (R-MD), sent a letter rebuking the policy. They argue it sends the wrong message to children, enables drug cartels including Chinese-linked operations, and increases road dangers by potentially ending safety-sensitive drug testing. Eagle Forum warns of public health risks like addiction, psychosis, and lower IQ, urging Trump to reconsider.

Senate leader Mitch McConnell echoes concerns over unintended hemp loopholes exploited for intoxicating delta-8 products. Despite GOP control of Congress, this rare right-flank defiance signals Trump’s evolving stance may strain party unity on traditional anti-drug principles. The administration balances medical validation with enforcement, as marijuana remains federally illegal post-rescheduling, though with reduced penalties.

Justice Department eases restrictions on some marijuana productshttps://t.co/XPoj2fM5S7

— James Rule XRP 👊😎 (@allthemoney) April 23, 2026

Broader Impacts and Shared Frustrations

Short-term, businesses save millions in taxes, spurring economic growth in state-legal markets; long-term, clinical research expands, validating medical benefits while hemp standards clarify CBD access. Medical patients gain research-backed options, but recreational sales face no federal change. Politically, the move appeals to cannabis-friendly voters and industry donors who backed Trump’s inauguration. Yet it underscores elite-driven policy diverging from founding principles of limited government and personal responsibility. Conservatives and liberals alike decry federal overreach—here, deep state DEA hearings drag on despite executive intent—failing everyday Americans chasing the dream through hard work. Uncertainties linger on exact timing and hearing outcomes.